Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: r-hTBP; r-hTBP-1; r-TBP-1; TBP; TBP 1; TBP I; TNF-BP1; Tumour necrosis factor antagonist; Tumour necrosis factor binding protein 1

Latest Information Update: 07 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Yeda
  • Class Anti-inflammatories; Antirheumatics; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Endometriosis; Psoriasis; Psoriatic arthritis; Reperfusion injury; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Canada (Parenteral)
  • 06 Sep 2005 Discontinued - Phase-II for Crohn's disease in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top